Does NIVOLUMAB Cause Interstitial lung disease? 1,538 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,538 reports of Interstitial lung disease have been filed in association with NIVOLUMAB (OPDIVO). This represents 1.8% of all adverse event reports for NIVOLUMAB.
1,538
Reports of Interstitial lung disease with NIVOLUMAB
1.8%
of all NIVOLUMAB reports
574
Deaths
961
Hospitalizations
How Dangerous Is Interstitial lung disease From NIVOLUMAB?
Of the 1,538 reports, 574 (37.3%) resulted in death, 961 (62.5%) required hospitalization, and 237 (15.4%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for NIVOLUMAB.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
TOCILIZUMAB (1,229)
Which NIVOLUMAB Alternatives Have Lower Interstitial lung disease Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE